The risk of cancer from azathioprlne as a treatment for multiple sclerosis [1]

European Journal of Neurology

Volumn 11, Issue 2, 2004, Pages 141-

  Taylor, L ^a   Hughes, R A C ^a   McPherson, K ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Azathioprine; Cancer; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA INTERFERON;

CANCER; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONFIDENCE INTERVAL; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LETTER; META ANALYSIS; MULTIPLE SCLEROSIS; POPULATION RESEARCH; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; CHEMICALLY INDUCED DISORDER; NEOPLASM;

AZATHIOPRINE; CLINICAL TRIALS; HUMANS; MULTIPLE SCLEROSIS; NEOPLASMS;

EID: 1642281053     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1351-5101.2003.00721.x     Document Type: Letter

References (5)

1. British and Dutch Multiple Sclerosis Azathioprine Trial Group (1988). Double-masked trial of azathioprine in multiple sclerosis. Lancet 2:179-183.
2. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G (1996). Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 46:1607-1612.
3. Kinlen LJ (1985). Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78(Suppl. A):44-49.
4. Palace J, Rothwell P (1997). New treatments and azathioprine in multiple sclerosis. Lancet 350:261.
5. Yudkin PL, Ellison GW, Ghezzi A et al. (1991). An overview of randomised controlled trials of azathioprine in the treatment of multiple sclerosis. Lancet 338:1051-1055.